KR20060124454A - Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 - Google Patents
Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 Download PDFInfo
- Publication number
- KR20060124454A KR20060124454A KR1020050046392A KR20050046392A KR20060124454A KR 20060124454 A KR20060124454 A KR 20060124454A KR 1020050046392 A KR1020050046392 A KR 1020050046392A KR 20050046392 A KR20050046392 A KR 20050046392A KR 20060124454 A KR20060124454 A KR 20060124454A
- Authority
- KR
- South Korea
- Prior art keywords
- sirna
- hcv
- nucleic acid
- rna
- acid molecule
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
- 서열번호 1 내지 36으로 구성되는 그룹으로부터 선택되는 염기 서열 또는 그의 상보적인 가닥 또는 그의 일부의 염기 서열을 포함하는 분리된 핵산 분자.
- 제 1항에 있어서, 서열 번호 4, 10, 16, 18, 19, 23, 29, 33 및 34로 구성된 그룹으로부터 선택되는 염기 서열 또는 그의 상보적인 가닥 또는 그의 일부의 염기서열을 포함하는 분리된 핵산 분자.
- 제 1항의 핵산분자로 구성된 센스 가닥 및 그의 안티 센스 가닥이 상보 결합된 분리된 핵산 분자.
- 제 3항에 있어서, 작은 간섭 RNA(siRNA)인 것을 특징으로 하는 분리된 핵산 분자.
- 제 3항에 있어서, 센스 가닥 및 안티센스 가닥의 3‘ 말단이 dTdT분자에 의해 연결된 것을 특징으로 하는 분리된 핵산 분자.
- 제 3항에 있어서, 센스 가닥 및 안티센스 가닥이 연결 분자에 의해서 공유 결합이 된 것을 특징으로 하는 분리된 핵산 분자.
- 제 5항에 있어서, 상기 연결 분자는 폴리뉴클레오티드 링커(linker)인 것을 특징으로 하는 분리된 핵산 분자.
- 제 5항에 있어서, 상기 연결 분자는 비-뉴클레오티드 링커(non-nucleotide linker)인 것을 특징으로 하는 분리된 핵산 분자.
- 제 1항에 있어서, C형 간염 바이러스의 RNA에 결합하는 것을 특징으로 하는 분리된 핵산 분자.
- 제 1항의 핵산분자의 염기 서열을 포함하는 DNA 벡터.
- 제 2항의 핵산분자의 염기 서열을 포함하는 DNA 벡터.
- 제 1항 내지 제 9항 중 어느 한 항의 핵산 분자 또는 제 10항 또는 제 11항의 DNA 벡터를 유효 성분으로 포함하는 HCV 감염으로 인한 질환 치료용 약학적 조성물.
- 제 12항에 있어서, 약학적으로 허용가능한 담체를 추가적으로 포함하는 것을 특징으로 하는 약학적 조성물.
- 제 1항 내지 제 9항 중 어느 한 항의 핵산 분자 또는 제 10항 또는 제 11 항의 DNA 벡터를 대상체에 주입하는 것을 포함하는 HCV 감염으로 인한 질환을 치료하는 방법.
- 도1의 pRNAiDu로 나타내어지는 siRNA 발현벡터(수탁번호: KCTC 10800BP).
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050046392A KR100733186B1 (ko) | 2005-05-31 | 2005-05-31 | Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 |
JP2008514550A JP2008541754A (ja) | 2005-05-31 | 2006-05-30 | Hcv特異的な低分子干渉rnaおよびそれを含むc型肝炎の治療剤 |
US11/915,975 US20090318531A1 (en) | 2005-05-31 | 2006-05-30 | Small Interfering RNA Specific For HCV And Therapeutic Agent For Hepatitis C Comprising The Same |
PCT/KR2006/002088 WO2006129961A1 (en) | 2005-05-31 | 2006-05-30 | Small interfering rna specific for hcv and therapeutic agent for hepatitis c comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050046392A KR100733186B1 (ko) | 2005-05-31 | 2005-05-31 | Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060124454A true KR20060124454A (ko) | 2006-12-05 |
KR100733186B1 KR100733186B1 (ko) | 2007-06-27 |
Family
ID=37481845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050046392A KR100733186B1 (ko) | 2005-05-31 | 2005-05-31 | Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090318531A1 (ko) |
JP (1) | JP2008541754A (ko) |
KR (1) | KR100733186B1 (ko) |
WO (1) | WO2006129961A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101384860B1 (ko) * | 2011-05-26 | 2014-04-15 | 단국대학교 산학협력단 | 표적 물질 특이적으로 siRNA를 방출하는 RNA 간섭용 조성물 및 이를 이용한 HCV 관련 질환 치료용 조성물 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008118013A2 (en) | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
CN111065736A (zh) * | 2017-06-07 | 2020-04-24 | 国立大学法人东京大学 | 针对颗粒状角膜变性症的基因治疗药物 |
CN107805643B (zh) * | 2017-09-15 | 2020-12-08 | 四川大学 | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA-DNA纳米系统及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE252154T1 (de) * | 1991-05-08 | 2003-11-15 | Chiron Corp | Genomische hcv-sequenzen für diagnostik und therapie |
US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
KR100502864B1 (ko) * | 2002-10-09 | 2005-07-22 | (주)팬바이오넷 | C형 간염바이러스의 복제 정량 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 hcv 저해제의 탐색방법 |
WO2005028650A2 (en) | 2003-09-16 | 2005-03-31 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
-
2005
- 2005-05-31 KR KR1020050046392A patent/KR100733186B1/ko active IP Right Grant
-
2006
- 2006-05-30 US US11/915,975 patent/US20090318531A1/en not_active Abandoned
- 2006-05-30 JP JP2008514550A patent/JP2008541754A/ja active Pending
- 2006-05-30 WO PCT/KR2006/002088 patent/WO2006129961A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101384860B1 (ko) * | 2011-05-26 | 2014-04-15 | 단국대학교 산학협력단 | 표적 물질 특이적으로 siRNA를 방출하는 RNA 간섭용 조성물 및 이를 이용한 HCV 관련 질환 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2006129961A1 (en) | 2006-12-07 |
JP2008541754A (ja) | 2008-11-27 |
US20090318531A1 (en) | 2009-12-24 |
KR100733186B1 (ko) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8426380B2 (en) | Inhibition of viral gene expression using small interfering RNA | |
KR101012595B1 (ko) | 작은 간섭 rna 및 이를 포함하는 b형 간염 바이러스 치료용 약학 조성물 | |
EP1747023B2 (en) | Methods and compositions for reducing hcv viral genome amounts in a target cell | |
US10982212B2 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
EP2316942B1 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
KR20090003147A (ko) | 소형 간섭 rna를 이용한 바이러스 유전자 발현의 억제 | |
Kim et al. | Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model | |
KR100733186B1 (ko) | Hcv 유전자에 특이적인 작은 간섭 rna 및 그를유효성분으로 포함하는 c형 간염 치료제 | |
JP4545091B2 (ja) | C型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
US20090203890A1 (en) | Hepatitis c antivirals | |
Shier et al. | Effect of RNA interference on the hepatitis C virus core expression in HepG2/C3A cells using genotype 4 isolates from Saudi patients | |
US20100260713A1 (en) | Compositions and Methods for the Inhibition of Hepatitis C Viral Replication with Structural Analogs | |
Ding et al. | Stably silencing of CD81 expression by small interfering RNAs targeting 3'-NTR inhibits HCV infection | |
AU2013257445B2 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
WO2012020836A1 (ja) | Rrm2のアンタゴニストを有効成分として含有するc型肝炎治療剤 | |
AU2016202897A1 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
MX2008003504A (en) | Inhibition of viral gene expression using small interfering rna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130405 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140408 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150310 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160418 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170328 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180411 Year of fee payment: 12 |